New York - Fresh from a successful public offering and new listing on the NASDAQ stock exchange, Trovagene CEO Antonius Schuh was given the honor of ringing the closing bell at Nasdaq’s Times Square marketsite. Standing in front of his management team, board of directors and special guests, Schuh reviewed Trovagene’s progress in developing faster, more accurate and less invasive diagnostics through urine analysis.
“Now we can watch how a cell in your body dies and releases its DNA into the bloodstream. That DNA signal travels through your kidney into your urine and there, we catch it,” he said. “If somebody has a certain infectious disease, a virus, a bacterium...we can diagnose it in your urine.”
For cancer patients, these diagnostic tools may help determine whether or not surgery to remove a cancer was completely successful. They may also help evaluate individual response to cancer therapy, and help determine if a patient is cancer-free following treatment. All of this may be possible without the need for additional blood, bone marrow or surgical biopsy specimens. The ability to perform complex molecular diagnosis on transrenal DNA, RNA and nucleic acids round in the urine make this possible. “We own that (technology), so we’re going to do it,” Schuh stated.
Trovagene (NASDAQ: TROV), (NASDAQ: TROVU), is headquartered in San Diego. Attending the closing bell ceremony were Trovagene founder and board member Gabriele Cerrone, other senior executives and board members, and a group of Fordham University business students who filled out the gallery.
NASDAQ Vice President David Wicks, executive host of the event, congratulated Trovagene for its May 30 NASDAQ listing and the success of its recent public offering. These developments, said Wicks, well-position Trovagene both in the capital markets and within the global molecular diagnostic industry, an industry with sales approaching $7 billion.
The recent public offering raised $10,580,000 million in gross proceeds. The company plans to use these to develop clinical diagnostics for oncology, infectious disease and potential acquisitions of other companies.
“Trovagene’s technology will enhance the likelihood that the right patient gets the right treatment at the right time, which is a welcome approach as the healthcare industry continues shifting to more personalized and individualized medicine,” said Wicks. “We look forward to watching Trovagene grow and innovate as a NASDAQ-listed company. We know you’re going to be back here celebrating more milestones.”
Wicks presented Schuh with a closing bell crystal to commemorate the event.
A video of the ceremony (on 6-14-12) can be viewed at:
www.nasdaq.com/marketsite/marketsite_events.stm
Contact:
Alex Michelini
michelinialex@aol.com
The Promotion Factory
5 E. 19th St.
New York, NY 10003
T. 212-217-9065 F. 212-217-9075
Trovagene, Inc., headquartered in San Diego, is a developer of molecular diagnostics through the detection of trans-renal DNA and RNA, short nucleic acid fragments originating from normal and diseased cell death that cross the kidney barrier and can be detected in urine. Trovagene is focusing on developing tests for cancer and, infectious diseases.
The Promotion Factory
5 E. 19th St., New York, NY 10003
michelinialex@aol.com
T. 212-217-9065
